Literature DB >> 30838289

Chemical Leukoderma: A Rare Adverse Effect of the Rotigotine Patch.

Neha Prakash1, Pratap Chand1.   

Abstract

Entities:  

Keywords:  adverse effect; chemical leukoderma; rotigotine; skin reaction

Year:  2017        PMID： 30838289      PMCID： PMC6353384          DOI： 10.1002/mdc3.12505

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN： 2330-1619


× No keyword cloud information.
  9 in total

1.  Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease.

Authors:  R L Watts; J Jankovic; C Waters; A Rajput; B Boroojerdi; J Rao
Journal:  Neurology       Date:  2007-01-03       Impact factor: 9.910

2.  Allergic contact dermatitis caused by rotigotine in a transdermal therapeutic system.

Authors:  Nadia Raison-Peyron; Bernard Guillot
Journal:  Contact Dermatitis       Date:  2016-08       Impact factor: 6.600

3.  Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study.

Authors:  Wolfgang Oertel; Claudia Trenkwalder; Heike Beneš; Luigi Ferini-Strambi; Birgit Högl; Werner Poewe; Karin Stiasny-Kolster; Andreas Fichtner; Erwin Schollmayer; Ralf Kohnen; Diego García-Borreguero
Journal:  Lancet Neurol       Date:  2011-06-24       Impact factor: 44.182

4.  Dopamine-induced apoptosis in human melanocytes involves generation of reactive oxygen species.

Authors:  C-Y Chu; Y-L Liu; H-C Chiu; S-H Jee
Journal:  Br J Dermatol       Date:  2006-06       Impact factor: 9.302

Review 5.  Allergic contact dermatitis caused by sodium metabisulfite: a challenging allergen: a case series and literature review.

Authors:  Juan García-Gavín; Joana Parente; An Goossens
Journal:  Contact Dermatitis       Date:  2012-08-01       Impact factor: 6.600

6.  Antioxidants and narrow band-UVB in the treatment of vitiligo: a double-blind placebo controlled trial.

Authors:  M L Dell'Anna; A Mastrofrancesco; R Sala; M Venturini; M Ottaviani; A P Vidolin; G Leone; P G Calzavara; W Westerhof; M Picardo
Journal:  Clin Exp Dermatol       Date:  2007-11       Impact factor: 3.470

7.  The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease.

Authors:  Dieter Scheller; Christoph Ullmer; Reinhard Berkels; Mirella Gwarek; Hermann Lübbert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-08-14       Impact factor: 3.000

8.  The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson's disease.

Authors:  Nir Giladi; Babak Boroojerdi; Erwin Surmann
Journal:  J Neural Transm (Vienna)       Date:  2013-03-19       Impact factor: 3.575

9.  Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial.

Authors:  Claudia Trenkwalder; Heike Benes; Werner Poewe; Wolfgang H Oertel; Diego Garcia-Borreguero; Al W de Weerd; Luigi Ferini-Strambi; Pasquale Montagna; Per Odin; Karin Stiasny-Kolster; Birgit Högl; K Ray Chaudhuri; Markku Partinen; Erwin Schollmayer; Ralf Kohnen
Journal:  Lancet Neurol       Date:  2008-07       Impact factor: 44.182
  9 in total
  1 in total

1.  Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist.

Authors:  Ronan Talty; Goran Micevic; Alice Wang; Christine J Ko; William Damsky
Journal:  Case Rep Dermatol       Date:  2022-08-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.